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Stanniocalcin 2 (STC2), a glycoprotein that regulates calcium and phosphate
homeostasis during mineral metabolism, appears to display multiple roles in
tumorigenesis and cancer progression. This study aimed to access the prognostic value
of STC2 in oral squamous cell carcinoma (OSCC) and its implications in oral
tumorigenesis. STC2 expression was examined in 2 independent cohorts of OSCC
tissues by immunohistochemistry. A loss-of-function strategy using shRNA targeting
STC2 was employed to investigate STC2 in vitro effects on proliferation, apoptosis,
migration, invasion, epithelial-mesenchymal transition (EMT) and possible activation of
signaling pathways. Moreover, STC2 effects were assessed in vivo in a xenograft mouse
cancer model. High expression of STC2 was significantly associated with poor disease-
specific survival (HR: 2.67, 95% CI: 1.37-5.21, p=0.001) and high rate of recurrence with
a hazard ratio of 2.80 (95% CI: 1.07-5.71, p=0.03). In vitro downregulation of STC2
expression in OSCC cells attenuated proliferation, migration and invasiveness while
increased apoptotic rates. In addition, the STC2 downregulation controlled EMT
phenotype of OSCC cells, with regulation on E-cadherin, vimentin, Snail1, Twist and
Zeb2. The reactivation of STC2 was observed in the STC2 knockdown cells in the in vivo
xenograft model, and no influence on tumor growth was observed. Modulation of STC2
expression levels did not alter consistently the phosphorylation status of CREB, ERK,
JNK, p38, p70 S6K, STAT3, STAT5A/B and AKT. Our findings suggest that STC2
overexpression is an independent marker of OSCC outcome and may contribute to tumor
progression via regulation of proliferation, survival and invasiveness of OSCC cells.
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1. Introduction
Oral squamous cell carcinoma (OSCC), the most common tumor in the head and
neck region, displays high incidence (more than 350,000 new cases every year) and
rates of mortality (approximately 177,000 deaths every year) [1]. Since OSCCs are
asymptomatic at early stages, most patients are diagnosed at advanced stage of
disease, resulting in a 5-year survival rate of approximately 50% [2]. Tumor invasion,
lymph node metastasis and high rates of locoregional recurrence are the main factors
leading to the death of patients with OSCC [3]. Therefore, biomarkers of early diagnosis,
prognosis and post-therapeutic monitoring are essential to improve clinical management
of OSCC. Indeed, several studies have reported potential biomarkers for predicting
OSCC progression and prognosis, however, their practical usefulness remains very
limited [4].
Stanniocalcins are glycoprotein hormones involved in calcium and phosphate
homeostasis [5]. Two isoforms are known in mammalians, stanniocalcin 1 and
stanniocalcin 2 (STC2), which are encoded by distinct genes [6]. Besides the canonical
function in calcium/phosphate regulation, promoting inorganic phosphate-induced
mineralization and preventing ectopic calcification, STC2 has been related to
proliferation, apoptosis, invasion and epithelial-mesenchymal transition (EMT) when
upregulated in tumors [7-9]. A recent systematic review and meta-analysis revealed that
high STC2 levels are frequently associated with advanced disease stage, lymph node
metastasis and vascular invasion, factors that suggest worse prognosis, and most
important, the high expression of STC2 significantly predicted poor overall survival [10].
However, in both female and male breast cancers, STC2 expression is a favorable
prognostic factor, extending disease-free and overall survival [11-13]. In head and neck
squamous cell carcinomas (HNSCC), STC2 expression level was associated with
aggressiveness, and in vitro studies confirmed its role regulating apoptosis, proliferation,
migration and invasion of HNSCC cells [14]. Upregulation of miR-206 on HNSCC
suppressed STC2 biological effects via PI3K-AKT signaling pathway [15]. Although the
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emerging literature suggests the clinical importance of STC2 in human cancers as
potential prognostic marker or therapeutic target, there are still very little molecular
details defining the mechanisms of action of those proteins in the control of oral
tumorigenesis.
In the current study we examined the expression levels of STC2 in OSCC clinical
samples to determine the prognostic impact of this protein for OSCC patients. Moreover,
we assessed whether STC2 knockdown influences OSCC cell proliferation, apoptosis,
migration, invasion and EMT in vitro and growth of xenograft tumors in vivo. The STC2
effects on the main signaling pathways, which is known to promote oral tumorigenesis,
were verified using the Luminex technology.
2.Materials and Methods
STC2 mRNA levels in previously published microarrays. To examine the
expression pattern of STC2 in published microarray data, we performed a meta-analysis
using data mining from the Oncomine® Research Premium Edition database
(https://www.oncomine.org). The first step was to identify previously published
microarray gene expression data comparing normal oral mucosa and OSCC. Filters for
selection of the data were studies that included STC2 in the analysis, comparing cancer
vs normal tissue, cancer type (squamous cell carcinoma) and primary tumor sites in the
oral cavity. After applying those filters, a total of 9 datasets (312 samples) from published
studies remained. The expression level was considered the median rank for the gene
across each of the analysis, and the given p-value was based in the median-ranked
analysis at a cut off 0.01 (p<0.01).
Tissue samples and clinicopathological data. This study included 2
independent cohorts of OSCC. The cohort 1 included 100 primary OSCCs diagnosed
and treated by radical surgery at 2 reference hospitals (UOPECCAN and CEONC
Cancer Hospitals) in Cascavel-Parana, between 1998 and 2008. The clinicopathological
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features of these patients were described previously [16]. The cohort 2 included 119
patients with OSCC treated at the Hospital Bom Pastor in Varginha-Minas Gerais,
between 1998 and 2014. In this cohort, a male prevalence was observed (n=86, 72.3%)
and the average age was 60.4 ± 11.4 years (range 21-87 years). Smoking was reported
by 84 (70.6%) patients and alcohol consumption by 57 (47.9%). Tumors were localized
in the tongue (n=95, 79.8%) or floor of mouth (n=24, 20.2%). Regarding clinical stage,
15 patients were stage I (12.6%), 32 were stage II (26.9%), 27 were stage III (22.7%)
and 45 were stage IV (37.8%). Surgery as monotherapy was performed in 17 (14.3%)
patients, whereas 50 (42%) were treated by a combination of surgery and postoperative
radiotherapy and 52 (43.7) by a combination of surgery and postoperative radiotherapy
and chemotherapy. A total of 21 (17.6%) tumors were classified as well-differentiated,
87 (73.1%) as moderately-differentiated and 11 (9.2%) as poorly-differentiated,
according to the WHO grading system. During follow up, 24 (20.2%) patients developed
recurrence (17 local, 5 regional and 2 distant). The overall survival ranged between 8 to
116 months, with a mean of 84 months. Twenty patients (17.1%) died due to the tumor.
The study was approved by the ethics review board of each of the hospitals affiliated
with the collaborative study, and revised by the Human Research Ethics Committee of
the School of Dentistry, University of Campinas (protocol number: 090/2011).
Immunohistochemistry. Three-μm tissue sections were deparaffinized and
hydrated using a graded series of ethanol until water. Sections were then subjected to
antigen retrieval with 0.01 M citrate buffer pH 6.0 in an electric pressure cooker and
incubation with 3% aqueous hydrogen peroxide for 15 min to quench endogenous
peroxidase. Two anti-STC2 antibodies were used : anti-STC2 monoclonal antibody
(Abcam, USA) diluted 1:50 (for the first cohort) and anti-STC2 polyclonal antibody
(Thermofisher, USA) diluted 1:100 (for the second cohort). After primary antibody, slides
were incubated with EnVision reagents (EnVision® + Dual Link System-HRP kit, Dako,
USA) and developed with 0.6 mg/ml 3,3'-diaminobenzidine tetrahydrochloride (Dako,
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USA) and Mayer's hematoxylin as counterstained. The control reactions were performed
by the exclusion of the primary antibody.
Immunoexpression of STC2 was semiquantitatively assessed taking in
consideration the number of positive cells and the intensity of staining. The number of
positive cells was graded in quartiles (0, 1: 1%-25% staining, 2: 26%-50% staining, 3:
51%-75% staining, and 4: 76%-100% staining), and the intensity of staining was scored
in 0: negative, 1: weak staining, 2: moderate staining and 3: strong staining. The 2 grades
were added together, resulting in scores that ranged from 0 to 7, and were classified as
low (0-4 score) and high (5-7 score) expression for comparative analysis.
Cell culture. The immortalized normal human gingival keratinocyte cell line (HGK)
was cultured in serum-free, low calcium media (Gibco’s Keratinocyte-SFM; Invitrogen,
USA) containing bovine pituitary extract, epidermal growth factor and antibiotics. Human
OSCC cells SCC-4, SCC-9, SCC-15 and SCC-25 were purchased from the American
Type Culture Collection (ATCC, USA) and cultured as recommended in a 1:1 mixture of
Dulbecco’s modified Eagle’s media and Ham’s F12 media (DMEM/F12; Invitrogen, USA)
supplemented with 10% fetal bovine serum (FBS), 400 ng/ml hydrocortisone (Sigma-
Aldrich, USA) and antibiotics. HSC-3, a highly invasive OSCC cell line, was obtained
from Japan Health Sciences Foundation (Osaka, Japan) and cultured in DMEM/F-12
media (Invitrogen, USA) supplemented with 10% FBS, 50 μg/ml ascorbic acid (Sigma-
Aldrich, USA), 400 ng/ml hydrocortisone (Sigma-Aldrich, USA) and antibiotics. All cells
were growth at 37°C in a humidified atmosphere of 5% CO2. Cells were regularly tested
for mycoplasma infection.
Quantitative PCR (qPCR). Total RNA from cell lines was isolated with TRIzol®
reagent (Invitrogen, USA) according to the manufacturer’s protocol. Following DNase I
treatment in order to eliminate genomic DNA contamination, 1 μg of total RNA per
sample was used to generate cDNA using Oligo-dT (Invitrogen, USA) and reverse
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transcriptase (Superscript II RT enzyme, Invitrogen, USA). Resulting cDNAs were
subjected to qPCR using specific primers and PowerUpTM SYBR® Green Master Mix
(Applied Biosystems) in the StepOnePlus Real Time PCR (Applied Biosystems). Gene
expression was determined by the ΔΔCT method and the housekeeping gene PPIA
(cyclophilin A) was used as a reference gene for data normalization. All primers used in
this study are described in Supplementary Table 1.
Stable short hairpin RNA (shRNA) knockdown of STC2. Stable knockdown of
STC2 expression in OSCC cell lines was achieved by the construction of lentiviral
vectors containing shRNA targeting human STC2 (MISSION® shRNA Lentiviral
Transduction Particles, Sigma-Aldrich, USA) or scrambled control shRNA (MISSION®
pLKO.1-puro Non-Mammalian shRNA Control, Sigma-Aldrich, USA) carrying a
puromycin antibiotic resistance gene. Oligonucleotide sequence for STC2 shRNA
(NM_003714.1) was
5’CCGGGAACAGTCTGAGTATTCTGATCTCGAGATCAGAATACTCAGACTGTTCTTT
TTTG3’. In essence, SCC-15 and HSC-3 cells grown in a 12-well plate at confluence of
70% were incubated with control or STC2 shRNA lentiviral particles at a multiplicity of
infection (MOI) of 1.5 in culture media containing 8 mg/ml of polybrene (Sigma-Aldrich,
USA) for 4 h. After washing with PBS, cells were cultured in fresh media for an additional
period of 48 h. Cells were then cultured for 10 days in the presence of 1 µg/ml of
puromycin dihydrochloride (Sigma-Aldrich, USA) to select resistant cells. Efficacy of
STC2 knockdown was determined by qPCR and western blot.
Western blot analysis. Proteins extracted from silenced cells were separated by
10% or 12% SDS-PAGE under reducing conditions and transferred onto nitrocellulose
membranes. The membranes were blocked with 10% non-fat dry milk in PBS containing
0.1% Tween-20, rinsed in the same buffer, and incubated for 2 h with the primary
antibodies: anti-STC2 (1∶100, Abcam, USA), anti-AKT (1:1000, Cell Signaling, USA),
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anti-pAKT (pS473, 1:1000, Cell Signaling, USA), anti-mTOR (1:1000, Cell Signaling,
USA), anti-pmTOR (pS2448, 1:1000, Cell Signaling, USA), anti-PI3K (1:1000, Cell
Signaling, USA), anti-E-cadherin (1:1000, clone 24E10, Cell Signaling, USA), anti-
vimentin (1:1000, clone D21H3, Cell Signaling, USA), anti-Snail1 (1:1000, clone C15D3,
Cell Signaling, USA), anti-Snail2 (1:1000, clone C19G7, Cell Signaling, USA), anti-β-
actin (1∶30000, Sigma-Aldrich, USA) and anti-GAPDH (1:3000, Santa Cruz, USA). After
washing, the protein bands were detected using enhanced chemiluminescence western
blotting system (GE Healthcare, USA) and signals captured with an Alliance 9.7
instrument (UVITEC, UK).
Bromodeoxyuridine (BrdU) incorporation assay. Proliferation rates were
determined by measuring BrdU incorporation into DNA using the Cell Proliferation ELISA
BrdU (Colorimetric) kit (Roche Applied Science, Germany). Briefly, BrdU antigen was
added to the cultures in 1:10 dilution and kept for 2 h at 37°C in 5% CO2. After incubation,
the medium was removed and manufacturer’s protocol was followed. Absorbance was
measured at 450 nm with correction at 655 nm.
Apoptosis analysis. Apoptosis index was determined by annexin V labeling.
Briefly, cells were harvested, washed and resuspended in the binding buffer (10 mM
HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 1.8 mM CaCl2) containing
annexin V-PE and 7-AAD (BD Biosciences, USA). Apoptosis was analyzed on a
FACScalibur flow cytometer equipped with an argon laser (BD Biosciences, USA) and
quantified as the number of annexin V-PE positive and 7-AAD negative cells divided by
the total number of cells.
Invasion and migration assays. Transwell migration and invasion assays were
performed in 6.5 mm inserts with 8 μm pore size (Corning, USA). For invasion assay,
membranes were coated with 50 μl of myogel [17]. Starved cells were plated into the
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upper chamber in 200 μl of serum-free DMEM/F12. As chemoattractant, 500 μl of
complete medium was used in the lower chamber. Experiment times varied between 24
h for migration and 48-72 h for invasion assays. Assessment of migration or invasion
was performed by gently removing cell in the interior part of the insert with a cotton swab.
Cells on the bottom of the membrane were fixed in 10% formalin for 30 min and stained
with 1% toluidine blue in 1% borax solution. The excess dye was washed out and cells
were then eluted in 1% SDS solution for 5 min. Absorbance was measured at 655 nm.
Gelatin zymography for MMP-2 and MMP-9. Zymography was performed with
conditioned media of the cells. Briefly, samples were submitted to 1-D electrophoresis
on 10% SDS-PAGE gels containing 1 mg/ml gelatin under nonreducing conditions. Gels
were stained with Coomassie blue, and gelatinolytic activity was identified as clear bands
against a blue background.
Tumorigenicity assay. To assess the growth of xenograft tumors in nude mice,
HSC3 cells (HSC-3 shRNA Control and HSC-3 shRNA STC2) were injected s.c. in the
flank of 12-week-old nude mice (10 animals per cell line). At 4-weeks, all mice were
euthanized, and tumors and multiple organs were examined grossly, collected, fixed in
10% formalin and then embedded in paraffin. At this moment, tumor size was measured
with a caliper, and volumes are reported as mm3, calculated by using the formula
volume=0.5 x length x width2. Five-micrometer sections were stained with hematoxylin
and eosin for histopathologic analysis and subjected to STC2 immunohistochemistry.
The animal experiment was reviewed and approved by the Ethical Committee on Animal
Research at the University of Campinas (protocol number 5279-1/2019).
Analysis of phosphorylated proteins by Luminex technology. Total proteins
from shRNA Control and shRNA STC2 cells were extracted and subjected to analysis
of the phosphorylated proteins CREB (pS133), ERK (pT185/pY187), JNK
11
(pT183/pY185), p38 (pT180/pY182), p70 S6K (pT412), STAT3 (pS727), STAT5A/B
(pY694/699), AKT (pS473) using a multiplex kit (Milliplex MAP Multi-Pathway #48-
680MAG, Millipore, USA), according to the manufacturer’s instructions. Positive and
negative controls (cellular lysates provided by the kit) were included in all analyses.
Statistical analysis. Associations between immunoexpression of STC2 and
clinicopathological parameters of the tumors were performed using cross-tabulation and
chi-square test. Survival curves were constructed based on the Kaplan-Meier method
and compared with the Log-rank test. For multivariate survival analysis, the Cox
proportional hazard model with a stepwise method was applied. All functional assays
were performed at least three times. Mann-Whitney U test or one-way analysis of
variance (ANOVA) with post-hoc comparisons based on the Tukey's multiple
comparisons test were applied. P values ≤0.05 were considered as significant.
3. Results
STC2 expression is associated with worse outcome of patients with OSCC
At first, we performed a meta-analysis with published microarray data compiled
from Oncomine® Research Premium Edition database. Comparison across microarray
gene expression studies showed that STC2 mRNA is significantly overexpressed in
OSCC samples compared with normal oral mucosa (p=0.01). The association between
STC2 expression and clinicopathological characteristics was verified in the cohort
containing 100 cases of OSCC (cohort 1). All cases showed cytoplasmatic staining of
STC2 in the tumor cells, with variable distribution and intensity. A high expression of
STC2 was detected in 64% of the tissue samples (Fig. 1A), while low expression was
found in 36% (Fig. 1B). As depicted in Table 1, the high expression of STC2 in OSCC
tissues was significantly associated with advanced clinical stage (p=0.02), and a
tendency towards association was observed with recurrence (p=0.07) and development
of a second primary tumor (p=0.06).
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We next assessed the association between STC2 expression and clinical
prognosis of OSCC patients. Outcomes were categorized as disease-specific survival,
time from treatment initiation until death due to cancer or last known date alive, and
disease-free survival, time from treatment initiation until diagnosis of the first recurrence
(local, regional or distant) or last follow-up information for those without recurrence. Only
survivors with follow-up information of at least 5 years were included. In comparison with
low expression, patients with high STC2 expression had a significantly shorten disease-
specific survival (HR: 2.68, 95% CI: 1.56-4.62, p=0.002) and a high risk of recurrence
(disease-free survival), yielding a HR of 2.37 (95% CI: 1.20-4.69, p=0.02) (Table 2). On
univariate analysis, significant associations between age (p=0.02) and advanced clinical
stage (p=0.02) with shorten disease-specific survival were detected (Table 2). On
multivariate survival analysis, age (HR: 1,95, 95% CI: 1.12-3.38, p=0.01) and STC2
expression (HR: 2.67, 95% CI: 1.37-5.21, p=0.001) were independently associated with
cancer-specific survival, whereas for disease-free survival, only STC2 (HR: 2.80, 95%
CI: 1.07-5.71, p=0.03) was significantly associated (Table 3).
Validation of association of STC2 with poor survival in an independent cohort
To confirm our findings, the expression levels of STC2 were investigated in an
independent set of OSCCs (cohort 2; details provided in materials and methods section),
applying a different anti-STC2 polyclonal antibody. Patients with high STC2 expression
showed a 5-year disease-specific survival of 46.0% compared with 84.5% for patients
with low STC2 immunoreactivity, yielding a HR of 2.68 (95% CI: 1.14-6.32, p=0.02, Fig.
2A). After 5 years, 88.5% of patients classified with low STC2 expression remained
without recurrence compared with 48.7% of those with high STC2 expression (HR: 2.66,
95% CI: 1.16-6.14, p=0.01, Fig. 2B).
Efficiency of STC2 knockdown in OSCC cells
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We investigated the expression of STC2 in one normal oral keratinocyte and five
OSCC cell lines. The STC2 mRNA levels were significantly higher in the OSCC cell lines
SCC-4 (p<0.01), SCC-9 (p<0.01), SCC-15 (p<0.0001) and HSC-3 (p<0.001) compared
with the spontaneously immortalized, but not transformed oral keratinocyte cell line HGK
(SFig. 1). Although high, the expression of STC2 in SCC-25 did not reach a significant
level. Considering SCC-15 and HSC-3 presented the highest STC2 expression among
OSCC cell lines, they were chosen for testing the effects of STC2 knockdown. We then
transduced SCC-15 and HSC-3 with a retroviral vector encoding a STC2 shRNA.
Compared to control cells (transduced with a universal shRNA control), STC2 mRNA
and protein levels were significant lower in STC2-silenced cells (Fig. 3).
STC2 controls proliferation, apoptosis, migration and invasion of OSCC cells
shRNA Control and shRNA STC2 cells were analyzed for cell proliferation,
apoptosis, migration and invasiveness. As shown in Fig. 4A, the proliferation of SCC-
15 (~73% reduction, p<0.0001) and HSC-3 (~64% reduction, p<0.001) was
significantly reduced following STC2 knockdown. The annexin V/7-AAD labeling assay
was employed to measure apoptosis of the shRNA. Flow cytometry revealed that the
number of apoptotic cells in the cells expressing the specific shRNA against STC2 was
significantly higher compared to respective controls (Fig. 4B). For SCC-15 shRNA STC2
cells, the increase in apoptosis rate was of approximately 40% (p<0.01) and for HSC-3
shRNA STC2 cells was approximately 19% (p<0.01). Both migration and invasion were
attenuated by STC2 knockdown. Compared to shRNA Control cells, the migration of
SCC-15 shRNA STC2 cells was reduced in 55% (p<0.001), whereas the reduction of
HSC-3 shRNA STC2 cell migration was approximately of 46% (p<0.01) (Fig. 4C).
Fewer SCC-15 (~50% reduction, p<0.001) and HSC-3 (~54% reduction, p<0.001) cells
with STC2 knockdown invaded the extracellular matrix compared to their corresponding
controls (Fig. 4D).
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STC2 is associated with EMT
To investigate whether STC2 is associated with acquisition of EMT properties, we
assessed the expression of EMT markers, including epithelial marker E-cadherin and
mesenchymal marker vimentin, as well as EMT transcription factors, after knockdown
STC2 expression. As indicated in Fig. 5A, cells expressing STC2-targeting shRNA had
significantly higher mRNA levels of E-cadherin (p<0.01 for SCC-15 cells and p<0.001 for
HSC-3 cells) and significantly lower expression of vimentin (p<0.05 for both SCC-15 and
HSC-3 cells) compared to control cells. Analysis of EMT transcription factors showed a
consistent decrease in the expression of Snail1 (p<0.0001 for both SCC-15 and HSC-
3), Twist (p<0.05 for SCC-15 and p<0.01 for HSC-3) and Zeb2 (p<0.001 for both SCC-
15 and HSC-3) in shRNA cells compared with controls (Fig. 5B). Zeb1 expression was
only significantly downregulated in HSC-3 cells (p<0.001), whereas no effects on Snail2
were detected in both cell lines (Fig. 5B). In the western blot analysis, levels of E-
cadherin were increased and levels of vimentin, Snail1 and Snail2 were decreased in
SCC-15 shRNA STC2 cells compared to SCC-15 shRNA Control cells (Fig. 5C). In
addition, we investigated MMP-2 and MMP-9 by qPCR and zymography. Levels of MMP-
2 and MMP-9 mRNA were significantly lower in STC2-silenced cells compared to their
corresponding control cells (Fig. 5D). In consonance, the gelatinolytic activities of MMP-
2 (band with 72 kDa) and MMP-9 (band with 92 kDa) were lower in conditioned medium
from shRNA STC2 cells compared to shRNA Control cells (Fig. 5E).
Expression of STC2 is reactivated in xenograft tumors
To further investigate the effects of STC2 on tumor growth in vivo, HSC-3 shRNA
control and HSC-3 shRNA STC2 cells were injected subcutaneously into nude mice. The
tumor nodules were visible in all mice, but no significant differences in volume were found
(SFig. 2). The histological features of tumors were quite similar, and
immunohistochemical analysis showed a clear cytoplasmic STC2 staining in HSC-3
shRNA STC2 cells, mainly in the peripheral cells of the tumor islands. Although some
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cells were completely negative, a reactivation of STC2 in vivo was observed in the tumors
formed by shRNA STC2 cells (SFig. 3).
Cell signaling in STC2 knockdown cells
A previous study demonstrated that the pro-tumorigenic effects of STC2 are
mediated by PI3K-AKT-Snail signaling [14]. We therefore examined the PI3K-AKT-
mTOR signaling pathway and their phosphorylation status through western blot. No
differences were observed in both SCC-15 and HSC-3 control and silencing cells (Fig.
6A). In order to further investigate the effects of STC2, we analyzed key proteins
associated with different pathways using a multiplex assay containing phosphorylated
CREB (pS133), ERK (pT185/pY187), JNK (pT183/pY185), p38 (pT180/pY182), p70 S6K
(pT412), STAT3 (pS727), STAT5A/B (pY694/699), AKT (pS473). None of the
investigated proteins was consistently and statistically different between shRNA Control
and shRNA STC2 cells, including AKT (Fig. 6B).
4. Discussion
Although STC2 was originally associated with calcium/phosphate regulation during
mineralization, it has been speculated that it is actually an oncoprotein since its
overexpression in many cancer types can predict outcome. Nonetheless, studies on
STC2 roles in OSCC are still limited. In this study, we found that STC2 is overexpressed
in OSCCs in comparison with normal oral mucosa, and its expression is associated with
advanced clinical stage, shortened disease-free survival and poor disease-specific
survival. These results are in line with previous ones regarding many solid cancers [10]
and with the findings of Yang and collaborators [14] on 298 patients with HNSCC (tumors
from oral cavity, oropharynx, pharynx and larynx). Interestingly, the expression levels of
STC2 were significantly related to the clinical stage of tumor but there were no large
alterations in the hazard ratios and its significance on multivariate compared to univariate
analysis in our survival analysis, and our findings were validated with a different antibody
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in an independent cohort, supporting that STC2 is a promising and independent
prognostic biomarker for OSCCs.
Modulation of STC2 expression has been investigated in different contexts and cell
lines. In this study, we found that STC2 knockdown inhibits proliferation, migration and
invasion, and promotes apoptosis of OSCC cells. In consonance with our results,
previous studies have demonstrated that STC2 regulates proliferation and colony
formation of lung and cervical cancer cells [8,18], and STC2-silencing reduces the
migration and invasion of colorectal cancer cells [19]. Moreover, loss of STC2 increased
radiation sensitivity of nasopharyngeal carcinoma cells, resulting in accumulation of the
cells at G1 and G2/M phases of the cell cycle [20]. Through inhibition of STC2, miR-485-
5p, miR-184, miR-206 and miR-1-3p inhibited proliferation, migration and invasion of
hepatocellular carcinoma, glioblastoma, HNSCC and gastric cancer cells, respectively
[15,21-23]. One recent study showed that STC2 overexpression in colon
adenocarcinoma, which allows its pro-tumorigenic roles, is dependent on Sp1 promoter
activation [24]. In contrast, overexpression of STC2 resulted in a significant impairment
of growth, migration and invasion in breast cancer cells [25,26]. In mouse xenograft
models of colorectal cancer [9] and HNSCC [14] and in neuroblastoma experimental
formation on the chick chorioallantoic membrane [27], STC2 accelerated tumor growth
and facilitated early metastasis. However, in our xenograft model, the expression of
STC2 was reactivated in most of the peripheral cells of tumor islands, and the cells
transduced with STC2 shRNA had quite similar tumor growth pattern than control cells.
It is possible that the complex in vivo tumor microenvironment set in this xenograft model
produces regulatory factors that reactivated STC2, such as hypoxia inducible factor 1
(HIF-1), a STC2 target gene that promotes proliferation and invasion in hypoxia, a feature
of this xenograft model [28,29]. Our findings support that overexpression of STC2
promotes oral tumorigenesis by regulation of proliferation, survival, migration and
invasion of OSCC cells, but STC2 might play different regulatory functions in the context
of cell tumor origin.
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EMT comprises the biological process by which cells transit between epithelial and
mesenchymal states and may acquire potent pro-tumorigenic features, including motility,
invasiveness, stemness, drug-resistance and the ability to form metastases [30]. This
transition can be regulated at multiple levels, but transcriptional control of gene
expression by EMT-inducing transcription factors, including Snails, Zebs and Twist, is
generally considered the master step in this process [31]. The main hallmarks of EMT
are the loss of the epithelial cell-cell adhesion molecule E-cadherin and acquisition of
mesenchymal cell marker vimentin, inducing phenotypical plasticity of cells [32].
Downregulation of STC2 was associated with gain of E-cadherin expression and loss of
vimentin, suggesting EMT regulation. In addition, STC2-knockdown cells showed
consistent inhibition of MMP-2 and MMP-9 and of EMT-inducing transcription factors
Snail1, Twist and Zeb2. Consistent with our findings, previous studies have revealed that
overexpression of STC2 may trigger EMT and MMP expression in ovarian [33], colorectal
[19,34] and HNSCC [14]. In this context, STC2 was closely related with
chemotherapeutic drug resistance in cervical, liver and colorectal cancer [18,34,35], and
cells overexpressing STC2 showed elevated expression of the pluripotency and self-
renewal markers Oct4 and Nanog [7]. Yang and collaborators [14] reported that STC2
could promote EMT in vitro through activating PI3K-AKT signaling. Unexpectedly, we
were unable to detect any alteration in expression or phosphorylation of PI3K, AKT and
mTOR concomitant with STC2 downregulation. Other signaling pathways frequently
altered in OSCCs, including CREB, ERK, JNK, p38, p70 S6K, STAT3 and STAT5A/B,
were not affected by silencing of STC2. Based on our results, we concluded that
overexpression of STC2 in OSCC cells plays an important role on acquisition of EMT
properties, but this effect is independent of PI3K-AKT-mTOR pathway.
In closing, our findings show that STC2 is upregulated in patients with OSCC and
its overexpression is significantly and independently associated with relapse and poor
outcome. In vitro downregulation of STC2 drove proliferation, survival and EMT
properties associated with migration and invasiveness of OSCC cells. Therefore, the
18
potential clinical applications of STC2 as a prognostic marker and as a therapeutic target
should be considered in OSCC.
Conflicts of interest
The authors have no conflicts of interest to declare.
Funding
This work was supported by grants from Fundação de Amparo à Pesquisa do
Estado de São Paulo - FAPESP (2018/16077-6 for RDC). MRD (2017/26764-8) is
research fellow supported by FAPESP, and LMPR received a grant from the Fundação
de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG (APQ 00205.16).
Authors contributions
AFC, MRD, CEO, DCB, CBD, GAB, ENSG and RDC carried out data acquisition
and analysis. IS-C and LMRP have contributed with the samples and their clinical
information. EG, TAS, RAF and HCG have participated in the design of the study. RDC
has designed and implemented the research protocol, and drafted the manuscript. All
authors have critically revised the manuscript.
References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 68 (2018) 394-424.
[2] A.C. Chi, T.A. Day, and B.W. Neville. Oral cavity and oropharyngeal squamous cell
carcinoma-an update. CA Cancer J Clin. 65 (2015) 401-421.
19
[3] L. Hingsammer, T. Seier, J. Ikenberg, P. Schumann, D. Zweifel, M. Rücker, M.
Bredell, M. Lanzer. The influence of lymph node ratio on survival and disease
recurrence in squamous cell carcinoma of the tongue. Int J Oral Maxillofac Surg. 48
(2019): 851-856.
[4] A. Almangush, I. Heikkinen, A.A. Mäkitie, R.D. Coletta, E. Läärä, I. Leivo, T. Salo.
Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic
review and meta-analysis. Br J Cancer. 117 (2017) 856-866.
[5] B.H. Yeung, A.Y. Law, C.K. Wong. Evolution and roles of stanniocalcin. Mol Cell
Endocrinol. 349 (2012): 272-80.
[6] S.J. Chu, J. Zhang, R. Zhang, W.W. Lu, J.S. Zhu. Evolution and functions of
stanniocalcins in cancer. Int J Immunopathol Pharmacol. 28 (2015) 14-20.
[7] P.H. Kim, S.S. Na, B. Lee, J.H. Kim, J.Y. Cho. Stanniocalcin 2 enhances
mesenchymal stem cell survival by suppressing oxidative stress. BMB Rep. 48
(2015): 702-707.
[8] S.S. Na, M.B. Aldonza, H.J. Sung, Y.I. Kim, Y.S. Son, S. Cho, J.Y. Cho. Stanniocalcin-
2 (STC2): A potential lung cancer biomarker promotes lung cancer metastasis and
progression. Biochim Biophys Acta. 1854 (2015): 668-676.
[9] B. Chen, X. Zeng, Y He, X Wang, Z. Liang, J. Liu, P. Zhang, H. Zhu, N. Xu, S. Liang.
STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells
through AKT-ERK signaling pathways. Oncotarget. 7 (2016) 71400-71416.
[10] L. Hu, Y. Zha, F. Kong, Y. Pan. Prognostic value of high stanniocalcin 2 expression
in solid cancers: A meta-analysis. Medicine (Baltimore). 98 (2019): e17432.
[11] S. Esseghir, A. Kennedy, P. Seedhar, A. Nerurkar, R. Poulsom, J.S. Reis-Filho, C.M.
Isacke. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast
cancer in a screen for signal sequence encoding proteins. Clin Cancer Res. 13
(2007): 3164-73.
[12] J.R. Todd, K.A. Ryall, S. Vyse, J.P. Wong, R.C. Natrajan, Y. Yuan, A.C. Tan, P.H.
Huang. Systematic analysis of tumour cell-extracellular matrix adhesion identifies
20
independent prognostic factors in breast cancer. Oncotarget. 7 (2016): 62939-
62953.
[13] C. Coulson-Gilmer, M.P. Humphries, S. Sundara Rajan, A. Droop, S. Jackson, A.
Condon, G. Cserni, L.B. Jordan, L.J. Jones, R. Kanthan, et al. Stanniocalcin 2
expression is associated with a favourable outcome in male breast cancer. J Pathol
Clin Res. 4 (2018) 241-249.
[14] S. Yang, Q. Ji, B. Chang, Y. Wang, Y. Zhu, D. Li, C. Huang, Y. Wang, G. Sun, L.
Zhang. STC2 promotes head and neck squamous cell carcinoma metastasis
through modulating the PI3K/AKT/Snail signaling. Oncotarget. 8 (2017): 5976-5991.
[15] T. Li, Y. Qin, Z. Zhen, H. Shen, T. Cong, E. Schiferle, S. Xiao. Long non-coding RNA
HOTAIR/microRNA-206 sponge regulates STC2 and further influences cell
biological functions in head and neck squamous cell carcinoma. Cell Prolif. 52
(2019): e12651.
[16] I. Sawazaki-Calone, A. Rangel, A.G. Bueno, C.F. Morais, H.M. Nagai, R.P. Kunz,
R.L. Souza, L. Rutkauskis, T. Salo, A. Almangush, et al. The prognostic value of
histopathological grading systems in oral squamous cell carcinomas. Oral Dis. 21
(2015): 755-761.
[17] T. Salo, M. Sutinen, E. Hoque Apu, E. Sundquist, N.K. Cervigne, C.E. de Oliveira,
S.U. Akram, S. Ohlmeier, F. Suomi, L. Eklund, et al. A novel human leiomyoma
tissue derived matrix for cell culture studies. BMC Cancer. 15 (2015): 981.
[18] Y. Wang, Y. Gao, H. Cheng, G. Yang, W. Tan. Stanniocalcin 2 promotes cell
proliferation and cisplatin resistance in cervical cancer. Biochem Biophys Res
Commun. 466 (2015): 362-368.
[19] Q. Li, X. Zhou, Z. Fang, Z. Zan. Effect of STC2 gene silencing on colorectal cancer
cells. Mol Med Rep. 20 (2019): 977-984.
[20] H. He, S. Qie, Q. Guo, S. Chen, C. Zou, T. Lu., Y. Su, J. Zong, H. Xu, D. He, et al.
Stanniocalcin 2 (STC2) expression promotes post-radiation survival, migration and
21
invasion of nasopharyngeal carcinoma cells. Cancer Manag Res. 11 (2019): 6411-
6424.
[21] G.X. Guo, Q.Y. Li, W.L. Ma, Z.H. Shi, X.Q. Ren. MicroRNA-485-5p suppresses cell
proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2.
Int J Clin Exp Pathol. 8 (2015): 12292-12299.
[22] Feng, L., Ma, J., Ji, H., Liu, Y., Hu, W. (2018) MiR-184 retarded the proliferation,
invasiveness and migration of glioblastoma cells by repressing stanniocalcin-2.
Pathol Oncol Res, 24(4): 853-860.
[23] J. Ke, B.H. Zhang, Y.Y. Li, M. Zhong, W. Ma, H. Xue, Y. Wen, Y.D. Cai. MiR-1-3p
suppresses cell proliferation and invasion and targets STC2 in gastric cancer. Eur
Rev Med Pharmacol Sci. 23 (2019): 8870-8877.
[24] J.B. Li, Z.X. Liu, R. Zhang, S.P. Ma, T. Lin, Y.X. Li, S.H. Yang, W.C. Zhang, Y.P.
Wang. Sp1 contributes to overexpression of stanniocalcin 2 through regulation of
promoter activity in colon adenocarcinoma. World J Gastroenterol. 25 (2019): 2776-
2787.
[25] S. Raulic, Y. Ramos-Valdes, G.E. DiMattia. Stanniocalcin 2 expression is regulated
by hormone signalling and negatively affects breast cancer cell viability in vitro. J
Endocrinol.197 (2008): 517-529.
[26] J. Hou, Z. Wang, H. Xu, L. Yang, X. Yu, Z. Yang, Y. Deng, J. Meng, Y. Feng, X.
Guo, et al. Stanniocalicin 2 suppresses breast cancer cell migration and invasion via
the PKC/claudin-1-mediated signaling. PLoS One. 10 (2015): e0122179.
[27] S. Volland, W. Kugler, L. Schweigerer, J. Wilting, J. Becker. Stanniocalcin 2
promotes invasion and is associated with metastatic stages in neuroblastoma. Int J
Cancer. 125 (2009): 2049-2057.
[28] A.Y. Law, C.K. Wong. Stanniocalcin-2 is a HIF-1 target gene that promotes cell
proliferation in hypoxia. Exp Cell Res. 316 (2010): 466-476.
[29] S. Miyazaki, H. Kikuchi, I. Iino, T. Uehara, T. Setoguchi, T. Fujita, Y. Hiramatsu, M.
Ohta, K. Kamiya, K. Kitagawa. Anti-VEGF antibody therapy induces tumor hypoxia
22
and stanniocalcin 2 expression and potentiates growth of human colon cancer
xenografts. Int J Cancer. 135 (2014): 295-307.
[30] Y. Zhang, R.A. Weinberg. Epithelial-to-mesenchymal transition in cancer:
complexity and opportunities. Front Med. 12 (2018): 361-373.
[31] P. Simeone, M. Trerotola, J. Franck, T. Cardon, M. Marchisio, I. Fournier, M. Salzet,
M. Maffia, D. Vergara. The multiverse nature of epithelial to mesenchymal transition.
Semin Cancer Biol, 58 (2019): 1-10.
[32] M. Pal, S. Bhattacharya, G. Kalyan, S. Hazra. Cadherin profiling for therapeutic
interventions in epithelial mesenchymal transition (EMT) and tumorigenesis. Exp
Cell Res. 368 (2018): 137-146.
[33] A.Y. Law, C.K. Wong. Stanniocalcin-2 promotes epithelial-mesenchymal transition
and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res. 316 (2010):
3425-34.
[34] H. Cheng, Z. Wu, C. Wu, X. Wang, S.S. Liow, Z. Li, Y.L. Wu. Overcoming STC2
mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA
cationic polyester in liver cancer cells. Mater Sci Eng C Mater Biol Appl. 83 (2018)
210-217.
[35] Q. Yuan, L. Zhan, L.L. Zhang, Q. Wang, J. Liu, Z.Y. Jiang, X.M. Hu, X.C. Yuan.
Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by
upregulating P-glycoprotein. Can J Physiol Pharmacol. 94 (2016): 929-935.
23
Figure legends
Fig. 1. Immunoexpression of STC2 in OSCCs. Representative immunohistochemical
analysis of STC2 in OSCC specimens. OSCC tumor cells showed variable distribution
and intensity of STC2. (A) OSCC specimen classified as low STC2 expression and (B)
sample with high expression of STC2.
Fig. 2. Kaplan-Meier curves. Curves for cancer-specific survival (A) and disease-free
survival (B) of patients with OSCC of cohort 2 based in STC2 expression levels.
Fig. 3. STC2 knockdown efficiency in SCC-15 and HSC-3 cells. Cells were transduced
with lentivirus expressing shRNA sequences against STC2 (shRNA STC2 cells) and
control (shRNA Control cells) as outlined in the methods. shRNA STC2 cells showed a
marked reduction in both mRNA (A) and protein levels (B) when compared with shRNA
Control cells. *p<0.0001
Fig. 4. Knockdown of STC2 modulates proliferation, apoptosis, migration and
invasion of OSCC cells. (A) Downregulation of STC2 significantly inhibited the
proliferative potential of SCC-15 and HSC-3, as revealed decreased BrdU incorporation.
(B) The proportion of apoptotic cells was increased in shRNA STC2 cells compared to
controls, as assessed by annexin V/7AAD binding assay. (C) Migration of SCC-15 and
HSC-3 cells was significantly decreased by STC2-specific shRNA, as revealed by
transwell migration assay. (D) Invasion of SCC-15 and HSC-3 cells was significantly
inhibited after STC2 knockdown. *p<0.01, **p<0.001, ***p<0.0001
Fig. 5. Modulation of STC2 mRNA levels affects epithelial-mesenchymal transition-
related markers. (A) Downregulation of STC2 significantly increased the expression of
E-cadherin while reduced vimentin in both SCC-15 and HSC-3 cells. (B) shRNA STC2
cells showed consistent decrease in the expression of Snail1, Twist and Zeb2 compared
24
with control cells. Zeb1 expression was only significantly downregulated in HSC-3 cells.
(C) Western blot analysis confirmed STC2 downregulation in SCC-15 cells is
accompanied by increased levels of E-cadherin and decreased levels of vimentin, Snail1
and Snail2. (D) Downregulation of STC2 significantly decreased the expression of MMP-
2 and MMP-9 in SCC-15 and HSC-3 cells as determined by qPCR. (E) Zymography
analysis of MMPs secreted by OSCC cells showed the inhibition of gelatinolytic activity
of MMP-2 and MMP-9 in shRNA STC2 cells. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001
Fig. 6. (A) Effects of STC2 knockdown on expression and phosphorylation of PI3K-
AKT-mTOR signaling proteins. Western blotting of PI3K and both phosphorylated and
total AKT and mTOR in shRNA Control and shRNA STC2 cells. (B) Activation of key-
proteins related to CREB, ERK, JNK, p38, p70 S6K, STAT3 and STAT5A/B pathway.
Values represent mean ± standard derivation of 3 independent experiments for each cell
line.
Supplementary figure legends
SFig. 1. STC2 is overexpressed in OSCC-derived cell lines. Total RNA from the
normal human gingival keratinocyte cell line (HGK) and from 5 human OSCC cell lines
(SCC-4, SCC-9, SCC-15, SCC-25 and HSC-3) were converted in cDNA and subjected
to qPCR. The STC2 mRNA levels were significantly higher in OSCC cells lines than in
HGK, with exception of SCC-25. 8p<0.01, **p<0.0001.
SFig. 2. The volume of xenograft tumors formed by HSC-3 shRNA Control and
HSC-3 shRNA STC2 cells. No differences in volume of tumors formed by HSC-3 shRNA
Control and HSC-3 shRNA STC2 cells were observed.
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SFig. 3. Representative images of the xenograft tumors formed by HSC-3 shRNA
Control cells (A and C) and HSC-3 shRNA STC2 cells (B and D). Tumors showed
similar histological features, and unexpectedly, the levels of STC2 were reactivated in
the peripheral HSC-3 shRNA STC2 cells of the tumor islands
Highlights
· Expression STC2 is a determinant of OSCC prognosis.
· STC2 A promotes proliferation, migration and invasion, and inhibits apoptosis.
· STC2 controls EMT phenotype of OSCC cells, with regulation on E-cadherin, vimentin,







Table 1. Association of the clinicopathological parameters of the OSCC with the







<57 years 18 (50) 31 (48.4)
≥57 years 18 (50) 33 (51.6) 0.88
Gender
Male 30 (83.3) 53 (82.8)
Female 6 (16.7) 11 (17.2) 0.94
Smoking habit
No 5 (16.1) 8 (15.7)
Yes 26 (83.9) 43 (84.3) 0.96
Drinking habit
No 8 (27.6) 13 (29.5)
Yes 21 (72.4) 31 (70.5) 0.85
Clinical stage
Early (I + II) 22 (62.9) 24 (38.1)
Advanced (III + IV) 13 (37.1) 39 (61.9) 0.02
Tumor site
Tongue 19 (52.8) 28 (43.8)
Others 17 (47.2) 36 (56.2) 0.38
Treatment
Surgery 14 (38.9) 26 (40.6)
Surgery + Radiotherapy 19 (52.8) 32 (50)
Surgery + Radiotherapy + Chemotherapy 3 (8.3) 6 (9.4) 0.96
Histological grade
Well-differentiated + Moderately-differentiated 34 (94.4) 54 (84.4)
Poorly-differentiated 2 (5.6) 10 (15.6) 0.13
Margin status
≥ 5 mm 35 (100) 60 (95.2)
< 5 mm 0 3 (4.8) 0.19
Recurrence
No 27 (77.11) 38 (59.4)
Yes 8 (22.9) 26 (40.6) 0.07
Second Primary Tumor
No 24 (68.6) 54 (84.4)
Yes 11 (31.4) 10 (15.6) 0.06
Table 2. Univariate analysis for disease-specific survival and disease-free survival of the OSCC patients.
Disease-specific survival Disease-free survival
Parameter % in 5 years HR (95% CI)/p value % in 5 years HR (95% CI)/p value
Age
<57 years 57.1 Reference 62.4 Reference
≥57 years 34.0 1.84 (1.07-3.16)/0.02 57.8 1.22 (0.62-2.39)/0.55
Gender
Male 45.3 Reference 63.5 Reference
Female 42.9 1.16 (0.55-2.48)/0.66 46.2 1.59 (0.64-3.97)/0.23
Smoking habit
No 51.8 Reference 68.3 Reference
Yes 46.9 1.42 (0.60-3.38)/0.35 47.1 1.99 (0.63-6.23)/0.12
Drinking habit
No 51.8 Reference 82.8 Reference
Yes 46.9 1.60 (0.82-3.12)/0.20 59.8 1.67 (0.68-4.06)/0.29
Clinical stage
Early (I + II) 54.2 Reference 62.2 Reference
Advanced (III + IV) 34.7 1.92 (1.11-3.31)/0.02 56.3 1.13 (0.57-2.24)/0.72
Tumor site
Tongue 54.0 Reference 63.2 Reference
Others 34.7 0.87 (0.51–1.50)/0.63 58.4 1.05 (0.53-2.07)/0.87
Treatment
Surgery 53.3 Reference 60.1 Reference
Surgery + Radiotherapy 50.0 1.22 (0.69-2.15)/0.51 59.2 1.13 (0.55-2.31)/0.72
Surgery + Radiotherapy + Chemotherapy 35.4 1.34 (0.55-3.27)/0.43 64.3 0.87 (0.26-2.89)/0.83
Histological grade
Well-differentiated + Moderately-differentiated 45.3 Reference 74.1 Reference
Poorly-differentiated 34.1 1.80 (0.66-4.93)/0.13 59.5 1.48 (0.44-4.95)/0.58
Margin status
≥ 5 mm 44.0 Reference 62.1 Reference
< 5 mm 50.0 0.92 (0.12-7.21)/0.94 100 NA
STC2
Low 63.4 Reference 74.5 Reference
High 34.4 2.68 (1.56-4.62)/0.002 52.0 2.37 (1.20-4.69)/0.02
Table 3. Cox multivariate analysis for the risk of death and recurrence.
Parameter Disease-specific survival Disease-free survival
HR (95% CI) p value HR (95% CI) p value
Age
<57 years Reference
≥57 years 1,95 (1.12-3.38) 0.01
STC2
Low Reference Reference





Supplementary Table 1. Description of primers used in the qPCR.
Primers Sequence (5’ → 3’)
STC2 Forward: GCATGTCACACGCAGGATTCT
Reverse: TGTCCGTTCCGCGAACA3
E-cadherin Forward: ACAGCCCCGCCTTATGATT3
Reverse: TCGGAACCGCTTCCTTCA
Vimentin Forward: GGCTCGTCACCTTCGTGAAT
Reverse: TCAATGTCAAGGGCCATCTTAA
Snail1 Forward: GCGTGTGCTCGGACCTTCT
Reverse: ATCCTGAGCAGCCGGACTCT
Snail2 Forward: GGAGCATACAGCCCCATCA
Reverse: TGGTAGCTGGGCGTGGAA
Zeb1 Forward: GCTTTCCCATTCTGGCTCCTA
Reverse: TCTTGGTCGCCCATTCACA
Zeb2 Forward: AAGATAGGTGGCGCGTGTTT
Reverse: ACTGACGTGTTACGCCTCTTCTAA
Twist Forward: GCGCTGCGGAAGATCATC3
Reverse: GCTTGAGGGTCTGAATCTTGCT
MMP-2 Forward: GTTCATTTGGCGGACTGT
Reverse: AGGGTGCTGGCTGAGTAG
MMP-9 Forward: CTTTGGACACGCACGAC
Reverse: CCACCTGGTTCAACTCACT
PPIA Forward: GCTTTGGGTCCAGGAATGG
Reverse: GTTGTCCACAGTCAGCAATGGT
